535 related articles for article (PubMed ID: 17283114)
1. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor.
Yang F; Huang X; Yi T; Yen Y; Moore DD; Huang W
Cancer Res; 2007 Feb; 67(3):863-7. PubMed ID: 17283114
[TBL] [Abstract][Full Text] [Related]
2. The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis.
Mencarelli A; Renga B; Migliorati M; Cipriani S; Distrutti E; Santucci L; Fiorucci S
J Immunol; 2009 Nov; 183(10):6657-66. PubMed ID: 19880446
[TBL] [Abstract][Full Text] [Related]
3. Role of nuclear receptors and hepatocyte-enriched transcription factors for Ntcp repression in biliary obstruction in mouse liver.
Zollner G; Wagner M; Fickert P; Geier A; Fuchsbichler A; Silbert D; Gumhold J; Zatloukal K; Kaser A; Tilg H; Denk H; Trauner M
Am J Physiol Gastrointest Liver Physiol; 2005 Nov; 289(5):G798-805. PubMed ID: 16002565
[TBL] [Abstract][Full Text] [Related]
4. The farnesoid X receptor induces very low density lipoprotein receptor gene expression.
Sirvent A; Claudel T; Martin G; Brozek J; Kosykh V; Darteil R; Hum DW; Fruchart JC; Staels B
FEBS Lett; 2004 May; 566(1-3):173-7. PubMed ID: 15147890
[TBL] [Abstract][Full Text] [Related]
5. The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis.
Cariou B
Diabetes Metab; 2008 Dec; 34(6 Pt 2):685-91. PubMed ID: 19195631
[TBL] [Abstract][Full Text] [Related]
6. FXR: a metabolic regulator and cell protector.
Wang YD; Chen WD; Moore DD; Huang W
Cell Res; 2008 Nov; 18(11):1087-95. PubMed ID: 18825165
[TBL] [Abstract][Full Text] [Related]
7. Bile acid retention and activation of endogenous hepatic farnesoid-X-receptor in the pathogenesis of fatty liver disease in ob/ob-mice.
Martin IV; Schmitt J; Minkenberg A; Mertens JC; Stieger B; Mullhaupt B; Geier A
Biol Chem; 2010 Dec; 391(12):1441-9. PubMed ID: 20868235
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents.
Boyer JL; Trauner M; Mennone A; Soroka CJ; Cai SY; Moustafa T; Zollner G; Lee JY; Ballatori N
Am J Physiol Gastrointest Liver Physiol; 2006 Jun; 290(6):G1124-30. PubMed ID: 16423920
[TBL] [Abstract][Full Text] [Related]
9. The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism.
Claudel T; Staels B; Kuipers F
Arterioscler Thromb Vasc Biol; 2005 Oct; 25(10):2020-30. PubMed ID: 16037564
[TBL] [Abstract][Full Text] [Related]
10. FXR, a multipurpose nuclear receptor.
Lee FY; Lee H; Hubbert ML; Edwards PA; Zhang Y
Trends Biochem Sci; 2006 Oct; 31(10):572-80. PubMed ID: 16908160
[TBL] [Abstract][Full Text] [Related]
11. FXR-deficiency confers increased susceptibility to torpor.
Cariou B; Bouchaert E; Abdelkarim M; Dumont J; Caron S; Fruchart JC; Burcelin R; Kuipers F; Staels B
FEBS Lett; 2007 Nov; 581(27):5191-8. PubMed ID: 17950284
[TBL] [Abstract][Full Text] [Related]
12. Bile acid-stimulated expression of the farnesoid X receptor enhances the immune response in Barrett esophagus.
Capello A; Moons LM; Van de Winkel A; Siersema PD; van Dekken H; Kuipers EJ; Kusters JG
Am J Gastroenterol; 2008 Jun; 103(6):1510-6. PubMed ID: 18510604
[TBL] [Abstract][Full Text] [Related]
13. Knockdown of ATP8B1 expression leads to specific downregulation of the bile acid sensor FXR in HepG2 cells: effect of the FXR agonist GW4064.
MartÃnez-Fernández P; Hierro L; Jara P; Alvarez L
Am J Physiol Gastrointest Liver Physiol; 2009 May; 296(5):G1119-29. PubMed ID: 19228886
[TBL] [Abstract][Full Text] [Related]
14. Bile acid signaling through FXR induces intracellular adhesion molecule-1 expression in mouse liver and human hepatocytes.
Qin P; Borges-Marcucci LA; Evans MJ; Harnish DC
Am J Physiol Gastrointest Liver Physiol; 2005 Aug; 289(2):G267-73. PubMed ID: 15817812
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia downregulates farnesoid X receptor via a hypoxia-inducible factor-independent but p38 mitogen-activated protein kinase-dependent pathway.
Fujino T; Murakami K; Ozawa I; Minegishi Y; Kashimura R; Akita T; Saitou S; Atsumi T; Sato T; Ando K; Hara S; Kikugawa K; Hayakawa M
FEBS J; 2009 Mar; 276(5):1319-32. PubMed ID: 19187229
[TBL] [Abstract][Full Text] [Related]
16. Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy.
Jiang T; Wang XX; Scherzer P; Wilson P; Tallman J; Takahashi H; Li J; Iwahashi M; Sutherland E; Arend L; Levi M
Diabetes; 2007 Oct; 56(10):2485-93. PubMed ID: 17660268
[TBL] [Abstract][Full Text] [Related]
17. Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation.
Degirolamo C; Modica S; Vacca M; Di Tullio G; Morgano A; D'Orazio A; Kannisto K; Parini P; Moschetta A
Hepatology; 2015 Jan; 61(1):161-70. PubMed ID: 24954587
[TBL] [Abstract][Full Text] [Related]
18. Role of bile acids and bile acid receptors in metabolic regulation.
Lefebvre P; Cariou B; Lien F; Kuipers F; Staels B
Physiol Rev; 2009 Jan; 89(1):147-91. PubMed ID: 19126757
[TBL] [Abstract][Full Text] [Related]
19. Bile acids override steatosis in farnesoid X receptor deficient mice in a model of non-alcoholic steatohepatitis.
Wu W; Liu X; Peng X; Xue R; Ji L; Shen X; Chen S; Gu J; Zhang S
Biochem Biophys Res Commun; 2014 May; 448(1):50-5. PubMed ID: 24747563
[TBL] [Abstract][Full Text] [Related]
20. A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia.
Evans MJ; Mahaney PE; Borges-Marcucci L; Lai K; Wang S; Krueger JA; Gardell SJ; Huard C; Martinez R; Vlasuk GP; Harnish DC
Am J Physiol Gastrointest Liver Physiol; 2009 Mar; 296(3):G543-52. PubMed ID: 19136377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
